About Us

Pursuing breakthroughs that could improve the lives of cancer patients

Bexion is a clinical-stage biopharmaceutical company advancing a new class of biologic therapy aimed at treating solid tumors while addressing the neuropathic pain current cancer treatments often cause

A novel approach to potentially unprecedented therapies

Bexion’s lead compound, BXQ-350, is a first-in-class sphingolipid metabolism modulator with the potential to address unmet medical needs across a variety of metastatic tumors. Currently, it’s being developed to treat solid tumors as well as thechemotherapy-induced peripheral neuropathy (CIPN) patients often experience with the current standard of care. Backed by promising initial clinical trial data, BXQ-350 shows potential in treating additional cancer types and broadening its neuropathic pain applications. We are urgently progressing our pipeline and exploring new possibilities to prolong and improve the lives of cancer patients.

Our Leaders

Bexion is led by innovative leaders with deep experience across biotech and oncology. Meet the team who is helping us achieve new and promising cancer therapies.

Board of Directors

Committed to patient advocacy

Bexion is proud to collaborate with patient organizations to better support the oncology community. We actively engage with our advocacy partners to ensure our priorities are aligned with those of cancer patients and their families.

To learn more about our advocacy partnerships and explore opportunities, please reach out.

Contact Us

Our Partners

Addressing an unmet medical need

BXQ-350 has potentially unprecedented anti-tumor, anti-neuropathy effects that show promise in treating cancer patients whose options for new therapies have historically been limited

Learn More